Notification of Drug Policy Revisions Effective February 1, 2025 (Posted December 2, 2024 | Providers

Shop Plans

Get Covered
Additional Coverage
Helpful Information
- Find Care
- FAQ
- Blog

Members

Type of Plans
- Medicare
- Health
- Dental
- Vision
Helpful Information
Special Groups

Employers

Get Started
Helpful Information

Agents

Get Started
Help Your Members

Notification of Drug Policy Revisions Effective February 1, 2025 (Posted December 2, 2024

Medical Drug Policy Name	Revised Criteria
Crovalimab-akkz (PiaSky™) Notification	Added requirement for trial and failure of two of the following: iptacopan (Fabhalta), pegcetacoplan (Empaveli), ravulizumab-cwvz (Ultomiris). Policy notification given 12/2/2024 for effective date 2/1/2025.

Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.

Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語

© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.